In this edition:
CYCLONE 2: Abemaciclib + Abiraterone in mCRPC
PSMAfore: HR-QoL & pain
PSMAfore: ctDNA & clinical outcomes
MAST: Metformin for low-risk prostate cancer
JNJ-6420 for mCRPC
Tarlatamab for NEPC
ARV-766 for mCRPC
NEPTUNES: ImS+ & checkpoint inhibitor therapy in mCRPC
ctDNA fraction as a biomarker of response to 177Lu-PSMA-617 in mCRPC
TALAPRO-2: ctDNA as a prognostic biomarker
Please login below to download this issue (PDF)